Form 4: Quest Diagnostics CEO James E. Davis Reports Stock and Option Transactions
SEC Form 4 Filing
CEO James E. Davis reports acquisition of restricted stock units and stock options in Quest Diagnostics.
Summary
- James E. Davis, CEO and President of Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership.
- On February 12, 2025, Davis acquired 18,149 shares of common stock through restricted stock units.
- Davis also acquired 69,633 non-qualified stock options with an exercise price of $165.30, exercisable in three equal annual installments starting February 12, 2026, and expiring on February 12, 2035.
- Following these transactions, Davis beneficially owns 144,117 shares of common stock and 69,633 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be seen as a positive sign of confidence, but doesn't necessarily indicate a major shift in the company's outlook.
Positives
- The acquisition of restricted stock units and stock options by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedule of the options (three equal annual installments) is a common practice.
- Comparing the size of the option grant and restricted stock units to those of peers in the diagnostic testing industry would provide further context.
Stakeholder Impact
- Shareholders may view the insider transactions as a sign of management's confidence in the company.
- Employees may be indirectly affected by the perceived alignment of management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 02/12/2026 | First vesting date for the non-qualified stock options. |
| 02/12/2035 | Expiration date for the non-qualified stock options. |
| 02/14/2025 | Date of signature by Attorney in Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.